Literature DB >> 17690183

Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice.

Karelle Leroy1, Alexis Bretteville, Katharina Schindowski, Emmanuel Gilissen, Michèle Authelet, Robert De Decker, Zehra Yilmaz, Luc Buée, Jean-Pierre Brion.   

Abstract

Neurodegenerative diseases characterized by brain and spinal cord involvement often show widespread accumulations of tau aggregates. We have generated a transgenic mouse line (Tg30tau) expressing in the forebrain and the spinal cord a human tau protein bearing two pathogenic mutations (P301S and G272V). These mice developed age-dependent brain and hippocampal atrophy, central and peripheral axonopathy, progressive motor impairment with neurogenic muscle atrophy, and neurofibrillary tangles and had decreased survival. Axonal spheroids and axonal atrophy developed early before neurofibrillary tangles. Neurofibrillary inclusions developed in neurons at 3 months and were of two types, suggestive of a selective vulnerability of neurons to form different types of fibrillary aggregates. A first type of tau-positive neurofibrillary tangles, more abundant in the forebrain, were composed of ribbon-like 19-nm-wide filaments and twisted paired helical filaments. A second type of tau and neurofilament-positive neurofibrillary tangles, more abundant in the spinal cord and the brainstem, were composed of 10-nm-wide neurofilaments and straight 19-nm filaments. Unbiased stereological analysis indicated that total number of pyramidal neurons and density of neurons in the lumbar spinal cord were not reduced up to 12 months in Tg30tau mice. This Tg30tau model thus provides evidence that axonopathy precedes tangle formation and that both lesions can be dissociated from overt neuronal loss in selected brain areas but not from neuronal dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690183      PMCID: PMC1959508          DOI: 10.2353/ajpath.2007.070345

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  71 in total

1.  Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1.

Authors:  A Boutajangout; K Leroy; N Touchet; M Authelet; V Blanchard; G Tremp; L Pradier; J P Brion
Journal:  Neurosci Lett       Date:  2002-01-18       Impact factor: 3.046

2.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

3.  Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform.

Authors:  T Ishihara; M Hong; B Zhang; Y Nakagawa; M K Lee; J Q Trojanowski; V M Lee
Journal:  Neuron       Date:  1999-11       Impact factor: 17.173

4.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein.

Authors:  K Spittaels; C Van den Haute; J Van Dorpe; K Bruynseels; K Vandezande; I Laenen; H Geerts; M Mercken; R Sciot; A Van Lommel; R Loos; F Van Leuven
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

5.  Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein.

Authors:  A Probst; J Götz; K H Wiederhold; M Tolnay; C Mistl; A L Jaton; M Hong; T Ishihara; V M Lee; J Q Trojanowski; R Jakes; R A Crowther; M G Spillantini; K Bürki; M Goedert
Journal:  Acta Neuropathol       Date:  2000-05       Impact factor: 17.088

6.  Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta.

Authors:  C H Reynolds; J C Betts; W P Blackstock; A R Nebreda; B H Anderton
Journal:  J Neurochem       Date:  2000-04       Impact factor: 5.372

7.  Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes.

Authors:  K Duff; H Knight; L M Refolo; S Sanders; X Yu; M Picciano; B Malester; M Hutton; J Adamson; M Goedert; K Burki; P Davies
Journal:  Neurobiol Dis       Date:  2000-04       Impact factor: 5.996

8.  The overlap of amyotrophic lateral sclerosis and frontotemporal dementia.

Authors:  Catherine Lomen-Hoerth; Thomas Anderson; Bruce Miller
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

Review 9.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

Authors:  L Buée; T Bussière; V Buée-Scherrer; A Delacourte; P R Hof
Journal:  Brain Res Brain Res Rev       Date:  2000-08

Review 10.  Tau function and dysfunction in neurons: its role in neurodegenerative disorders.

Authors:  Jesús Avila; Filip Lim; Francisco Moreno; Carlos Belmonte; A Claudio Cuello
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

View more
  42 in total

Review 1.  Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system.

Authors:  Nicholas M Kanaan; Gustavo F Pigino; Scott T Brady; Orly Lazarov; Lester I Binder; Gerardo A Morfini
Journal:  Exp Neurol       Date:  2012-06-19       Impact factor: 5.330

2.  Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Authors:  Laetitia Troquier; Raphaelle Caillierez; Sylvie Burnouf; Francisco J Fernandez-Gomez; Marie-Eve Grosjean; Nadege Zommer; Nicolas Sergeant; Susanna Schraen-Maschke; David Blum; Luc Buee
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 4.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

5.  Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat.

Authors:  Robert J Phillips; Gary C Walter; Brittany E Ringer; Katherine M Higgs; Terry L Powley
Journal:  Exp Neurol       Date:  2009-08-05       Impact factor: 5.330

6.  Loss of MAP function leads to hippocampal synapse loss and deficits in the Morris Water Maze with aging.

Authors:  Qiu-Lan Ma; Xiaohong Zuo; Fusheng Yang; Oliver J Ubeda; Dana J Gant; Mher Alaverdyan; Nicolae C Kiosea; Sean Nazari; Ping Ping Chen; Fatiha Nothias; Piu Chan; Edmond Teng; Sally A Frautschy; Greg M Cole
Journal:  J Neurosci       Date:  2014-05-21       Impact factor: 6.167

Review 7.  The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease.

Authors:  Johanna L Crimins; Amy Pooler; Manuela Polydoro; Jennifer I Luebke; Tara L Spires-Jones
Journal:  Ageing Res Rev       Date:  2013-03-22       Impact factor: 10.895

8.  Transgenic expression of the amyloid-beta precursor protein-intracellular domain does not induce Alzheimer's Disease-like traits in vivo.

Authors:  Luca Giliberto; Cristina d'Abramo; Christopher Michael Acker; Peter Davies; Luciano D'Adamio
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

Review 9.  Improved behavioral response as a valid biomarker for drug screening program in transgenic rodent models of tauopathies.

Authors:  Miroslava Korenova; Zuzana Stozicka
Journal:  Cell Mol Neurobiol       Date:  2009-03-13       Impact factor: 5.046

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.